Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

10x Genomics TXG

Healthcare  —  Health Information Services
85.71 1.60 1.90% as of 25 Sep
Market cap
$11.1B
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

10x Genomics (TXG) Business Profile

Updated before January 2025

Company Overview

10x Genomics (NASDAQ: TXG) is a biotechnology company that specializes in advancing genomic research through innovative technologies. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company is headquartered in Pleasanton, California. Serge Saxonov, one of the co-founders, currently serves as the CEO, leading the company with a vision to accelerate the understanding of biology and improve human health. Since its inception, 10x Genomics has been at the forefront of single-cell and spatial biology, providing researchers with tools to explore complex biological systems at unprecedented resolution.

The company went public in September 2019, raising significant capital to expand its operations and product offerings. Over the years, 10x Genomics has established itself as a leader in the life sciences industry, with a strong focus on innovation and customer-centric solutions. The company collaborates with academic institutions, pharmaceutical companies, and clinical researchers worldwide to drive breakthroughs in genomics and translational research.

Core Business Segments

10x Genomics operates through three primary business segments, each offering cutting-edge products and services designed to empower researchers:

1. Single-Cell Genomics

This segment focuses on enabling researchers to analyze individual cells within a complex tissue or sample. Key products include:

  • Chromium Single Cell Gene Expression: A platform that allows researchers to study gene expression at the single-cell level, providing insights into cellular diversity and function.
  • Chromium Single Cell Immune Profiling: Designed for immunology research, this product helps in understanding immune cell diversity and function.
  • Chromium Single Cell Multiome ATAC + Gene Expression: A dual-assay solution that combines epigenomic and transcriptomic data from the same cell.

2. Spatial Genomics

This segment enables researchers to map gene expression within the spatial context of tissues. Key products include:

  • Visium Spatial Gene Expression: A platform that provides spatially resolved transcriptomics, allowing researchers to visualize gene activity within tissue sections.
  • Visium CytAssist: A complementary tool that enhances the spatial resolution of tissue samples.

3. In Situ Analysis

This emerging segment focuses on high-resolution, in situ analysis of biological samples. Key products include:

  • Xenium In Situ Platform: A next-generation platform for spatially resolved, high-throughput molecular profiling.

Business Model

10x Genomics operates on a hybrid business model that integrates hardware, consumables, and software to provide end-to-end solutions for genomic research. The company generates revenue through the sale of instruments, consumables, and software licenses. Consumables, such as reagents and microfluidic chips, represent a significant portion of the company’s recurring revenue, as they are essential for running experiments on 10x Genomics’ platforms.

The company also offers bioinformatics software, such as Cell Ranger and Loupe Browser, which are designed to analyze and visualize data generated by its platforms. By providing a comprehensive ecosystem of products and services, 10x Genomics ensures customer loyalty and creates a sustainable revenue stream.

Strategic Direction

10x Genomics is committed to driving innovation and expanding its product portfolio to address the evolving needs of the research community. Key strategic priorities include:

  • Product Innovation: The company continues to invest heavily in research and development to introduce new platforms and enhance existing ones. Recent advancements in spatial and in situ technologies highlight this commitment.
  • Global Expansion: 10x Genomics aims to increase its presence in international markets, particularly in Asia and Europe, where demand for genomic research tools is growing.
  • Sustainability Goals: The company is exploring ways to minimize its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Clinical Applications: While currently focused on research applications, 10x Genomics is exploring opportunities to expand into clinical diagnostics and personalized medicine.

Competitive Landscape

10x Genomics operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  • Illumina: A leader in next-generation sequencing (NGS) technologies.
  • Bio-Rad Laboratories: Offers a range of genomic and proteomic research tools.
  • Fluidigm (now Standard BioTools): Specializes in single-cell analysis and microfluidics.
  • NanoString Technologies: Competes in the spatial genomics space with its GeoMx Digital Spatial Profiler.
  • Becton, Dickinson and Company (BD): Provides flow cytometry and single-cell analysis solutions.

Despite the competition, 10x Genomics differentiates itself through its focus on innovation, ease of use, and comprehensive product ecosystem.

Risk Factors

10x Genomics faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on academic and pharmaceutical research funding, which can be influenced by economic conditions and government policies.
  • Supply Chain Disruptions: As a hardware and consumables provider, 10x Genomics is vulnerable to supply chain challenges, including shortages of raw materials and manufacturing delays.
  • Regulatory Risks: Expanding into clinical applications may expose the company to stringent regulatory requirements and potential delays in product approvals.
  • Competition: The rapidly evolving genomics market poses the risk of technological obsolescence and pricing pressures.

Recent Developments

10x Genomics has made significant strides in recent years, including:

  • Launch of the Xenium In Situ Platform: This platform represents a major advancement in spatial biology, offering high-resolution molecular profiling.
  • Acquisition of ReadCoor and Cartana: These acquisitions have strengthened the company’s capabilities in spatial genomics and in situ analysis.
  • Expansion of Manufacturing Facilities: To meet growing demand, 10x Genomics has invested in expanding its production capacity.
  • Response to COVID-19: The company played a role in pandemic research by providing tools for studying the immune response to SARS-CoV-2.

Investment Considerations

Strengths:

  • Market Leadership: 10x Genomics is a pioneer in single-cell and spatial biology, with a strong brand and customer base.
  • Recurring Revenue: The sale of consumables ensures a steady revenue stream.
  • Innovation-Driven: The company’s focus on R&D positions it well for long-term growth.

Risks:

  • High Valuation: As a growth-oriented company, 10x Genomics may face scrutiny over its valuation.
  • Dependence on Research Funding: Economic downturns could impact funding for academic and pharmaceutical research.
  • Regulatory Challenges: Expanding into clinical markets may introduce new risks.

Conclusion

10x Genomics is a trailblazer in the genomics industry, offering innovative solutions that empower researchers to explore biology at an unprecedented scale. With a strong focus on innovation, a comprehensive product ecosystem, and a growing global presence, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with market dependence, competition, and regulatory challenges. Overall, 10x Genomics remains a compelling player in the life sciences sector, with significant potential to drive advancements in genomics and personalized medicine.